Nuwellis Inc vs Atlassian Corporation PLC — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Atlassian Corporation PLC trades at $207 (market cap $51.53B). The key difference: Atlassian Corporation PLC is far larger — about 23422.7× Nuwellis Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Atlassian Corporation PLC for 65 Days on average.
| NUWE | TEAM | |
|---|---|---|
Market Cap | $2.20M | $51.53B |
Volume | 121,544 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $146.65 | $203.57 |
52-Week Low | $0.68 | $57.15 |
Typical Hold Time | 26 Days | 65 Days |
Enterprise Value | -$1.52M | $51.52B |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Atlassian (TEAM) trades at $205.09, up 4.81% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with moving averages supporting upward momentum, though RSI suggests potential overbought conditions. Revenue growth remains robust at $5.22B for 2025, with improving margins despite negative net income. Recent news highlights accelerating cloud migration and AI adoption driving investor optimism.
Outlook remains positive with 69.77% analyst buy ratings and a $140B addressable market growing at 14% annually. Key risks include persistent negative profitability, high valuation multiples, and competitive pressures. The stock trades above consensus price target of $191.16, suggesting near-term consolidation potential despite long-term growth catalysts from AI and cloud expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →